Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2000 Aug 21;10(16):1803-6.

CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.

Author information

1
Department of Discovery Chemistry, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK. ian_t_forbes@sbphrd.com

Abstract

A weak HTS hit at the CCR2B receptor has been converted into a potent antagonist by array SAR studies. Selectivity over the closely related CCR5 receptor is also achieved.

PMID:
10969972
DOI:
10.1016/s0960-894x(00)00347-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center